Major Pharma-Deal in India Sun Pharma Takes Over Ranbaxy
Sun Pharmaceutical Industries has begun the integration of Ranbaxy’s business following the successful closure of its merger. The merger has fortified Sun Pharma’s position as the world’s fifth largest specialty generic pharmaceutical company and the top ranking Indian Pharma company with significant lead in market share.
New Delhi/India – The combined entity’s manufacturing footprint covers 5 continents with products sold in over 150 nations with a stronger presence in US, India, Asia, Europe, South Africa, CIS & Russia and Latin America. Sun Pharma now offers a large basket of specialty and generic products encompassing a broad range of chronic and acute prescription drugs as well as a ready foray into the global consumer healthcare market.
The integrated culture theme, “Growing Together”, represents the core objective of this merger focusing on improving productivity, compliance commitment, focus on quality and sustainable growth.
The combination allows Sun Pharma to:
- 1. Significantly expand its R&D capabilities and global presence, especially across emerging markets
- 2. Enhance product portfolio and market depth in India, US as well as Rest of the World markets
- 3. Improve strategic flexibility, ability to pursue partnerships and strengthen M&A bandwidth
Following the closure of this transaction, Ranbaxy will be delisted from the Indian Stock Exchanges.
Commenting on the combined entity’s priorities, Managing Director, Sun Pharma, Dilip Shanghvi said "It is an important milestone in the history of Sun Pharma as we enter into a new phase of growth. We will continue to focus on gaining trust of the Regulators globally while continuing to develop products based on patient needs and leverage them to become brand leaders globally.”